Novel Insight: CUEDC2 Expression of Potential Prognostic Value in Esophageal Squamous Cell Cancer

Abstract Background Esophageal squamous cell cancer (ESCC) poses serious threats to human life. Hence, the search for effective bio-markers to predict the occurrence and development of ESCC is of emerging significance.Methods We used immunohistochemistry to semi-quantitatively detect CUEDC2 expression in 50 ESCC cases and 20 adjacent tissues, analyzing the relationship with clinicopathological parameters and prognosis outcomes. Additionally, investigating the differences between CUEDC2 and CD68 in ESCC.Result CUEDC2 expression was higher in 9 ESCC tissues and lower in 41 ESCC tissues. Whereas, CUEDC2 expression was higher in 11 adjacent tissues and lower of the rest 9 cases, and the differences were statistically significant (P<0.05).CUEDC2 and ESCC clinicopathological characteristics exerted no significant difference (P>0.05). Via the Kaplan-Meier method, CUEDC2 and tumor grade demonstrated an impact on ESCC prognosis ( P<0.05). By double-immunofluorescence, there was an expression difference between CD68 and CUEDC2, and the difference was statistically significant (P<0.05). There showed co-localization of CUEDC2 and CD68 fluorescence.Conclusion CUEDC2 was relatively lower expressed in ESCC and higher in adjacent tissues. There was no significant difference between CUEDC2 and ESCC clinicopathological characteristics.CUEDC2 and tumor grade presented an impact on ESCC prognosis. There might be an interaction between CD68 and CUEDC2.

Download Full-text

Preoperative serum C-reactive protein levels and postoperative survival in patients with esophageal squamous cell carcinoma: a propensity score matching analysis

Journal of Cardiothoracic Surgery ◽

10.1186/s13019-019-0981-0 ◽

2019 ◽

Vol 14 (1) ◽

Author(s):

Wei Huang ◽

Leilei Wu ◽

Xuan Liu ◽

Hao Long ◽

Tiehua Rong ◽

...

Keyword(s):

Squamous Cell ◽

Squamous Cell Cancer ◽

Cell Cancer ◽

Survival Rates ◽

Tumor Grade ◽

Tnm Stage ◽

C Reactive Protein ◽

Reactive Protein ◽

Preoperative Serum ◽

The Difference

Abstract Objectives This study tested the relationship between preoperative serum C-reactive protein (CRP) levels and cancer-specific prognosis in patients with esophageal squamous cell carcinoma who have undergone curative resection. Methods We conducted a retrospective study on 961 patients with esophageal squamous cell cancer who underwent curative esophagectomy from 2006 to 2012 at the Sun Yat-sen University Cancer Center. Preoperative serum CRP levels were determined, and a cutoff value of 5.0 mg/mL was established. Propensity score matching (PSM) was performed to reduce the selection bias between patients with low CRP (≤ 5.0 mg/mL) and those with high CRP (> 5.0 mg/mL) levels based on age, tumor-lymph node-metastasis (TNM) stage, and tumor grade. The prognostic value of preoperative CRP levels was determined using life table, Kaplan–Meier, and Cox proportional hazards analyzes. Results In the unmatched cohort, the 3-year and 5-year survival rates were 57 and 53%, respectively, in patients with high preoperative CRP levels (> 5.0 mg/mL) and 68 and 56%, respectively, in those with low preoperative CRP levels (≤ 5.0 mg/mL). The difference in the survival rates of the 2 groups was significant (p = 0.004). Univariate survival analysis revealed that the preoperative CRP levels, TNM stage, tumor grade, drinking history, and anastomosis method were prognostic factors for overall survival (OS). Before conducting PSM, the low-CRP group had a lower age (p = 0.001), lower histological grade (p = 0.086), and lower TNM stage (p = 0.254). After PSM, 176 patients with low CRP levels and 176 of those with high CRP levels were enrolled in the analysis. In the matched cohort, the 3-year and 5-year survival rates were 56 and 50%, respectively, in patients with high preoperative CRP levels (> 5.0 mg/mL) and 68 and 56%, respectively, in those with low preoperative CRP levels (≤ 5.0 mg/mL). The difference in the survival rates between the low- and high-CRP groups was significant (p = 0.044). Multivariate analysis of the matched patients revealed that the TNM stage and preoperative CRP level were independent prognostic factors for OS. Conclusions A high preoperative CRP level (> 5.0 mg/mL) predicts worse survival prognosis in patients who have undergone curative resection for esophageal squamous cell cancer.

Download Full-text

Total Care for Oral Tracheal and Esophageal Squamous Cell Cancer Employing Transnasal Esophagogastroduodenoscopy

Nihon Kikan Shokudoka Gakkai Kaiho ◽

10.2468/jbes.65.113 ◽

2014 ◽

Vol 65 (2) ◽

pp. 113-114

Author(s):

K. Kawada ◽

Y. Nakajima ◽

T. Kawano

Keyword(s):

Squamous Cell ◽

Squamous Cell Cancer ◽

Cell Cancer ◽

Esophageal Squamous Cell Cancer ◽

Total Care

Download Full-text

FDA approves pembrolizumab for advanced esophageal squamous cell cancer

Case Medical Research ◽

10.31525/cmr-19086be ◽

2019 ◽

Author(s):

Keyword(s):

Squamous Cell ◽

Squamous Cell Cancer ◽

Cell Cancer ◽

Esophageal Squamous Cell Cancer

Download Full-text

Topical oro-dispersible budesonide tablets for stricture prevention after near circumferential ESD for esophageal squamous cell cancer – a case report

Zeitschrift für Gastroenterologie ◽

10.1055/a-1409-1076 ◽

2021 ◽

Author(s):

Daniel Mathies ◽

Tsuneo Oyama ◽

Ingo Steinbrück ◽

Franz Ludwig Dumoulin

Keyword(s):

Case Report ◽

High Risk ◽

Endoscopic Resection ◽

Squamous Cell ◽

Squamous Cell Cancer ◽

Cell Cancer ◽

Complete Healing ◽

Esophageal Squamous Cell Cancer ◽

Stricture Formation ◽

Local Injections

Abstract Background Endoscopic resection is the treatment of choice for early esophageal cancers. However, resections comprising more than 70–80 % of the circumference are associated with a high risk of stricture formation. Currently, repetitive local injections and/or systemic steroids are given for prevention. Case report We present here the case of a 78-year-old male patient who had a near circumferential endoscopic submucosal dissection for a pT1a mm, L0, V0, R0, G2 esophageal squamous cell cancer. At the end of endoscopic resection, 80 mg of triamcinolone was injected locally. The patient was then treated with oro-dispersible budesonide tablets (2 × 1 mg/day) and nystatin (4 × 100 000 I.E.) for 8 weeks. This treatment resulted in complete healing without any stricture formation and did not result in any complications. Discussion Treatment with orodispersible budesonide tablets could help prevent strictures after large endoscopic resections in the esophagus.

Download Full-text

Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

Scientific Reports ◽

10.1038/s41598-021-86019-2 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Yu-Chieh Ho ◽

Yuan-Chun Lai ◽

Hsuan-Yu Lin ◽

Ming-Hui Ko ◽

Sheng-Hung Wang ◽

...

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Squamous Cell ◽

Squamous Cell Cancer ◽

Performance Status ◽

Cell Cancer ◽

Esophageal Squamous Cell Cancer ◽

Lymphocyte Ratio ◽

Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

Download Full-text